Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. - Test2 - elhamkhani - TriplyDB

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

http://www.wikidata.org/entity/Q24535835

about

Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical research B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target Safety, activity, and immune correlates of anti-PD-1 antibody in cancer Role of PD-1 in HIV pathogenesis and as target for therapy The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer Melanoma immunotherapy dominates the field A Perspective of Immunotherapy for Prostate Cancer Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy The role of pembrolizumab in the treatment of advanced non-small cell lung cancer Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy Role of the tumor microenvironment in mature B-cell lymphoid malignancies Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects PD-1/PD-L1 blockade in cancer treatment: perspectives and issues Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Viro-immune therapy: A new strategy for treatment of pancreatic cancer Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression Single-cell analysis tools for drug discovery and development Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications New developments in the management of advanced melanoma - role of pembrolizumab Pembrolizumab The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients Nivolumab in the treatment of malignant melanoma: review of the literature The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity Overcoming T cell exhaustion in infection and cancer Current advances in immunotherapy for pancreatic cancer Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention Immunotherapy for prostate cancer: recent developments and future challenges Role of immunotherapy for renal cell cancer in 2011 Pathways and therapeutic targets in melanoma PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions Optimal management of metastatic melanoma: current strategies and future directions

P2860

Q24289253-EF9242A1-450E-44D9-9F49-D9C7B632863A Q24550945-91A5DFBB-5F35-499A-A8E3-7A677E57C612 Q24559442-7668CDE7-24CA-4CE4-A271-7AAD2C59C4B8 Q24633070-C6F06A56-5C29-486D-A1C2-D930FD978C26 Q24634293-B6459529-8969-46AA-8E74-378D2EC74D49 Q24670319-2FC3D18C-9428-41FD-8835-550C574C6F6B Q24685406-2D9A387B-5F2E-41DE-8AF8-604A4287F543 Q26738671-C4B0E3D3-A2F6-46E1-92D8-669B4A868D54 Q26741277-673A82DB-3D7A-4D2B-B65F-8D0FBAC9E989 Q26742047-C3A358A9-B8A0-4733-972A-F4E355DABB87 Q26742107-0E093FFB-534E-450B-8B23-EDDC448B0DB3 Q26744076-5E05DFB4-4642-443B-8777-F15CC7BB5D32 Q26744527-CC530177-4E62-4352-912C-91B2B7F71A4B Q26745516-D73C15D6-C0C0-429A-B158-704A41A16C6D Q26748775-CFBBD2DC-C92C-4837-AAEE-175DB2E9D253 Q26749244-41BC7EB9-BC73-4FBC-B244-DC37886339B4 Q26753082-21FFF344-7A2C-425E-B546-B8C3000BED53 Q26768641-66780455-C4F2-42C9-92C4-47A8B3C89536 Q26769884-B1C9E2AC-0C14-4848-A397-87B543C7209F Q26774641-C921845D-6035-4D38-9017-7CA038DB638D Q26775034-8A9A4474-C094-483B-9F08-5976710A85A3 Q26775189-F5907E72-32D0-420F-85A4-FCC75F0E5E5D Q26775754-C4514B37-4483-4857-BD4C-442A09E24283 Q26775769-222AC812-823D-4F35-B2DE-8296CC7065F4 Q26777111-CBFF7B7F-F73F-4F9D-AE0C-24A9E1FCF8EE Q26779221-84DE41C0-DCF6-4C16-BCC9-EC37169C65D3 Q26781931-51B6EF35-95BE-43C8-8F48-C1F933E8561C Q26796435-9B3F26F6-4FEC-419E-89C7-5065B9D9CCBE Q26797478-788269B0-9BE8-4847-8685-D9C040D32E45 Q26798330-1552F3F7-AADB-4A9B-B256-A13FC04B8386 Q26829847-241C33AA-1CA8-41DF-8128-B081F4D55A0A Q26829885-534DB67B-8E0F-44B5-942F-56D401343847 Q26830170-D3C25B49-D1F6-49B3-BD3A-C3D039348783 Q26850218-05231694-7E2F-4B51-8C55-066D8A73D4C1 Q26852388-A5458CED-DA11-4A82-90FD-07E23C24BED0 Q26853453-696C9462-9B97-4B26-8910-CB2E2F181D12 Q26865736-CDDEED8B-7A90-4359-8DFF-FC088CB1BD62 Q26865789-617B0A95-2FC8-489C-8EA4-BA842FBD46A6 Q26865859-B08AEAD2-6539-440C-BD44-30C6BE5F5B09 Q26997338-79BEECB3-05D7-4BEB-B954-3C1EB3FE97DB

P2860

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

http://www.wikidata.org/entity/Q24535835

description

2002 nî lūn-bûn

@nan

2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Involvement of PD-L1 on tumor ...... mmunotherapy by PD-L1 blockade

@nl

Involvement of PD-L1 on tumor ...... munotherapy by PD-L1 blockade.

@ast

Involvement of PD-L1 on tumor ...... munotherapy by PD-L1 blockade.

@en

type

label

Involvement of PD-L1 on tumor ...... mmunotherapy by PD-L1 blockade

@nl

Involvement of PD-L1 on tumor ...... munotherapy by PD-L1 blockade.

@ast

Involvement of PD-L1 on tumor ...... munotherapy by PD-L1 blockade.

@en

prefLabel

Involvement of PD-L1 on tumor ...... mmunotherapy by PD-L1 blockade

@nl

Involvement of PD-L1 on tumor ...... munotherapy by PD-L1 blockade.

@ast

Involvement of PD-L1 on tumor ...... munotherapy by PD-L1 blockade.

@en

P1433

Q24535835-ADC05452-2417-41F3-AE61-688E1D6C6124

P1476

Q24535835-5EFB2479-2B62-4951-B9CD-AC7BEF4140C2

P2093

Q24535835-11F59086-00B0-4ABB-9EF4-DB2D5FA831BE

Q24535835-5DDA6E54-6F28-4D8A-A1B3-09CD86A82C7F

Q24535835-D37E3607-814D-4CBF-B34D-5792BBD63BA9

Q24535835-D8D3291D-9E85-4299-AD72-77D99DC7EA17

P2860

Q24535835-06A253B8-1E2D-4F78-90F4-847ED1976FB5

Q24535835-15BF8072-FA39-47F1-8DF4-1CFB732C0DDE

Q24535835-190349FA-D98A-4C09-BB3C-BA6F3756E2A7

Q24535835-2C8FF032-5142-4241-A499-1F5D785A75BE

Q24535835-384C1662-DCFF-4CAA-9AFC-2E799344BDD2

Q24535835-4169C54F-7499-4350-A5B0-71DEAFF20AF6

Q24535835-5666F95A-E702-459F-81C7-CC9DEB55726C

Q24535835-64CED539-71DD-45C8-B663-0BEB984993F0

Q24535835-6AE0382E-BC21-4C1B-9C94-94472F5306F2

Q24535835-74A123BF-1594-44D3-AB60-907E42C407E0

P304

Q24535835-F28308C9-D739-4342-8542-4D2F6FE72B5D

P31

Q24535835-424AF9C4-34DF-45FA-AE74-ECC14895EBEA

P3181

Q24535835-92061727-E056-43CD-8267-656EFFB675C2

P356

Q24535835-78DBFFBF-EAF5-4BF0-8D3A-852E5EA607F5

P407

Q24535835-C645E8F2-1EDB-4857-8B2A-0E67FE29A81C

P433

Q24535835-B2B92936-FA09-4E1A-A74E-64317058C731

P478

Q24535835-A6A639D2-C001-4373-ABFB-ED6DE603CB93

P50

Q24535835-7A03E8F0-3BC1-4332-825C-E4632FEBE6C9

Q24535835-CFC55FD9-0476-436D-9183-5215C4FD380C

P577

Q24535835-3E99E031-2EB2-451E-ADE2-852A2883FE76

P5875

Q24535835-E6448143-8C9C-412D-8C30-0BE30EFEA5BD

P698

Q24535835-AD371EE5-4C8E-4EB0-A3FF-ECD71D894A29

P921

Q24535835-E7B4E11B-1EFD-41D5-B39F-2417444C6C67

P932

Q24535835-DE8247A4-CE32-469E-B57B-47E9400FE290

P3181

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Involvement of PD-L1 on tumor ...... munotherapy by PD-L1 blockade.

@en

P2093

Masayoshi Ishida

http://www.w3.org/2001/XMLSchema#string

Nagahiro Minato

http://www.w3.org/2001/XMLSchema#string

Taku Okazaki

http://www.w3.org/2001/XMLSchema#string

Yoshiko Iwai

http://www.w3.org/2001/XMLSchema#string

P2860

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Enhancement of antitumor immunity by CTLA-4 blockade

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

ICOS is essential for effective T-helper-cell responses

The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

P304

12293-12297

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

380118

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.192461099

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

Yoshimasa Tanaka

P577

2002-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11171458

http://www.w3.org/2001/XMLSchema#string

P698

12218188

http://www.w3.org/2001/XMLSchema#string

P921

P932

129438

http://www.w3.org/2001/XMLSchema#string